<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02308098</url>
  </required_header>
  <id_info>
    <org_study_id>3103013</org_study_id>
    <nct_id>NCT02308098</nct_id>
  </id_info>
  <brief_title>To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product</brief_title>
  <acronym>BUFODIL</acronym>
  <official_title>Study Comparing Bronchodilator Efficacy of Two Dry Powder Inhalers, Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler; a Randomised, Double-blind, Double-dummy, Multicentre, Single Dose, Crossover Study in Asthmatic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm equivalent bronchodilator efficacy of the test
      product compared to the reference product.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average FEV1</measure>
    <time_frame>12 h</time_frame>
    <description>FEV1 determined from serial spirometry and calculated on the basis of area under the curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum FEV1</measure>
    <time_frame>12 h</time_frame>
    <description>Maximum FEV1 over the 12-hour serial assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at 12 h</measure>
    <time_frame>12 h</time_frame>
    <description>FEV1 at 12 hours post-dose</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symbicort Turbuhaler 320/9 ug/inhalation 4 inh</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Symbicort Turbuhaler 320/9 ug/inhalation 4 inh Placebo Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symbicort Turbuhaler 320/9 ug/inhalation 1 inh</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Symbicort Turbuhaler 320/9 ug/inhalation 1 inh Placebo Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh</intervention_name>
    <arm_group_label>Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh</intervention_name>
    <arm_group_label>Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort Turbuhaler 320/9 ug/inhalation 4 inh</intervention_name>
    <arm_group_label>Symbicort Turbuhaler 320/9 ug/inhalation 4 inh</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort Turbuhaler 320/9 ug/inhalation 1inh</intervention_name>
    <arm_group_label>Symbicort Turbuhaler 320/9 ug/inhalation 1 inh</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh</intervention_name>
    <arm_group_label>Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh</intervention_name>
    <arm_group_label>Symbicort Turbuhaler 320/9 ug/inhalation 4 inh</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh</intervention_name>
    <arm_group_label>Symbicort Turbuhaler 320/9 ug/inhalation 1 inh</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh</intervention_name>
    <arm_group_label>Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion criteria:

          -  Written informed consent

          -  Asthma diagnosis for at least 6 months

          -  Prebronchodilator FEV1 45-90% of the predicted value

          -  Demonstration of reversible airway obstruction

          -  Stable asthma on the same regular treatment for at least 4 weeks before the study

          -  Non-smoker for at least 6 months before the study

        Main exclusion criteria

          -  Respiratory infection within 4 weeks before the study

          -  Smoking history of more than 10 pack-years

          -  Other severe chronic respiratory disease than asthma

          -  Concurrent illness that would interfere with the interpretation of the study results
             or constitute a health risk for the patient if he/she takes part in the study

          -  Corrected QT interval &gt; 450 ms in males or &gt; 470 ms in females

          -  Abnormal serum potassium value or other clinically significant laboratory finding

          -  Systolic blood pressure over 180 mmHg and/or diastolic blood pressure over 100 mmHg

          -  Treatment with a long-acting β2-agonist, a xanthine-derivative, a β-blocker or with a
             corticosteroid (other than inhaled) within 4 weeks before the study

          -  Use of drugs that prolong QT-interval

          -  Women who are pregnant, breast-feeding or without reliable contraception

          -  Participation in another clinical drug study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hristo Metev, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Specialized Hospital for Active Treatment for Pneumophthisiatric Diseases Dr Dimitar Gramatikov-Ruse EOOD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment for Pneumophthisiatric Diseases Dr Dimitar Gramatikov-Ruse EOOD</name>
      <address>
        <city>Ruse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <removed_countries>
    <country>Hungary</country>
  </removed_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2014</study_first_submitted>
  <study_first_submitted_qc>December 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <last_update_submitted>June 29, 2015</last_update_submitted>
  <last_update_submitted_qc>June 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Bronchodilator Agents</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

